Effects of Empagliflozin on Kidney and Cardiac Magnetic Resonance Imaging Measures in Patients With CKD: An EMPA-KIDNEY Mechanistic Substudy.

Zhu D., Judge PK., Francis ST., Che Z., Rayner JJ., Buchanan C., Mayne KJ., Stevens W., Bley T., Bhandary N., Byrne C., Cejka V., Chapman D., Cox EF., Dasgupta T., Malijan GB., Nicholas R., Phelan P., Smith E., Tunnicliffe EM., Wooding N., Nangaku M., Cherney DZI., Selby NM., Taal M., Steubl D., Aoqui C., Wanner C., Emberson JR., Landray MJ., Baigent C., Staplin N., Herrington WG., Haynes R., EMPA-KIDNEY Collaborative Group .

DOI

10.1053/j.ajkd.2025.09.022

Type

Journal article

Publication Date

2025-12-01T00:00:00+00:00

Addresses

Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK; Oxford Kidney Unit, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Keywords

EMPA-KIDNEY Collaborative Group

Permalink More information Close